Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention

AIDS Research and Human Retroviruses

Volumn 25, Issue 11, 2009, Pages 1099-1106

  Chi, Benjamin H ^a,b   Ellis, Giovanina M ^c   Chintu, Namwinga ^a,b   Cantrell, Ronald A ^a,b,g   Sinkala, Moses ^b,d   Aldrovandi, Grace M ^e   Warrier, Ranjit ^a,b   Mbewe, Felistas ^a   Nakamura, Kyle ^e   Stringer, Elizabeth M ^a,b   Frenkel, Lisa M ^c,f   Stringer, Jeffrey S A ^a,b  

^a CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d Catholic Medical Mission Board   (Zambia)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NEVIRAPINE; OLIGONUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA MICROARRAY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAPARTUM CARE; LABOR; MAJOR CLINICAL STUDY; OLIGONUCLEOTIDE LIGATION ASSAY; PERINATAL INFECTION; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VIRUS CONCENTRATION; VIRUS DETECTION; VIRUS RESISTANCE;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MUTATION; NEVIRAPINE; PHOSPHONIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 71949103631     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0088     Document Type: Article

References (25)

1. Eshleman SH, Mracna M, Guay LA, et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001;15:1951-1957.
2. Shapiro RL, Thior I, Gilbert PB, et al.: Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana. AIDS 2006;20:1281-1288.
3. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al.: Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004;351:229-240.
4. Cressey TR, Jourdain G, Lallemant MJ, et al.: Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005; 38:283-288.
5. McIntyre J, Martinson N, Gray G, et al.: Addition of short-course combivir (CBV) to single dose viramune (sdNVP) for the prevention of mother-to-child transmission (pMTCT) of HIV-1 can significantly decrease the development of maternal and paediatric NNRTI-resistant virus. In the 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janiero, Brazil, 24-27 July, 2005 [Abstract TuFo0204].
6. Chaix ML, Ekouevi DK, Rouet F, et al.: Low risk of nevirapine resistance mutations in the prevention of motherto- child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire. J Infect Dis 2006;193:482-487.
7. Chi BH, Sinkala M, Mbewe F, et al.: Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: An open-label randomised trial. Lancet 2007; 370:1698-1705.
8. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, and Boucher C: Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol 1999;37:2291-2296.
9. Flys T, Nissley DV, Claasen CW, et al.: Sensitive drugresistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005;192:24-29.
10. Johnson JA, Li JF, Morris L, et al.: Emergence of drugresistant HIV-1 after intrapartum administration of singledose nevirapine is substantially underestimated. J Infect Dis 2005;192:16-23.
11. Church JD, Jones D, Flys T, et al.: Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006;8:430-432; quiz 527.
12. Troyer RM, Lalonde MS, Fraundorf E, et al.: A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res Hum Retroviruses 2008;24: 235-250.
13. Chi BH, Chintu N, Cantrell RA, et al.: Addition of singledose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission. J Acquir Immune Defic Syndr 2008;48:220-223.
14. Stringer JS, Zulu I, Levy J, et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-793.
15. Chi BH, Chintu N, Lee A, Stringer EM, Sinkala M, and Stringer JS: Expanded services for the prevention of motherto- child HIV transmission: Field acceptability of a pilot program in Lusaka, Zambia. J Acquir Immune Defic Syndr 2007;45:125-127.
16. Beck IA, Mahalanabis M, Pepper G, et al.: Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 2002;40:1413-1419.
17. Ellis GM, Mahalanabis M, Beck IA, et al.: Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 2004;42:3670-3674.
18. Frenkel LM, Wagner LE, 2nd, Atwood SM, Cummins TJ, and Dewhurst S: Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol 1995;33:342-347.
19. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, and Frenkel LM: Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Microbiol 1998;36:569-572.
20. Tobin NH, Learn GH, Holte SE, et al.: Evidence that lowlevel viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus. J Virol 2005;79:9625-9634.
21. Lockman S, Shapiro RL, Smeaton LM, et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007;356:135-147.
22. Chi BH, Sinkala M, Stringer EM, et al.: Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine. AIDS 2007;21:957-964.
23. Weidle PJ, Stringer JS, McConnell MS, et al.: Effectiveness of non-nucleoside reverse transcriptase inhibitator-containing antiretroviral therapy in women previously exposed to a single dose of nevirapine: A multi-country cohort study. In the 14th Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2007.
24. Peuchant O, Thiebaut R, Capdepont S, et al.: Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008;22:1417-1423.
25. Coovadia A, Hunt G, Abrams EJ, et al.: Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reversetranscriptase inhibitor-based therapy. Clin Infect Dis 2009;48(4):462-472.